Haisco Pharmaceutical Group Co. Ltd. has identified compounds acting as TNF-α/TNF receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis and rheumatoid arthritis.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized prodrugs of deuterated baloxavir marboxil derivatives acting as cap-dependent endonuclease (CEN) (influenza virus) inhibitors reported to be useful for the treatment of influenza viral infections.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Myrobalan Therapeutics Nanjing Co. Ltd. has divulged uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists reported to be useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease.
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. and Suzhou Kelun Pharmaceutical Co. Ltd. have identified carboxylic acid ester compounds reported to be useful for anesthesia.
Beijing Chempion Biotechnology Co. Ltd. has synthesized antibody-drug conjugates comprising antibodies targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Beijing Avistone Pharmaceuticals Biotechnology Co. Ltd. has disclosed spiro/bridged ring compounds acting as HER2 (erbB2) (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla mutant]) inhibitors reported to be useful for the treatment of atherosclerosis, cancer and pulmonary fibrosis.
Casma Therapeutics Inc. has developed bicyclic heteroaromatic compounds acting as mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of Duchenne muscular dystrophy, neurodegeneration, atherosclerosis, cancer, infections, liver, lysosomal storage and inflammatory bowel diseases.
Simon Fraser University, TRIUMF and the University of British Columbia have disclosed radiolabeled compounds reported to be useful for the diagnosis of cancer.